Alibaba’s new open source model QwQ-32B matches DeepSeek-R1 with way smaller compute requirements
While DeepSeek-R1 operates with 671 billion parameters, QwQ-32B achieves comparable performance with a much smaller footprint.Read More
Category Added in a WPeMatico Campaign
While DeepSeek-R1 operates with 671 billion parameters, QwQ-32B achieves comparable performance with a much smaller footprint.Read More
The General Services Administration plans to sell hundreds of government buildings, including FBI headquarters. Use our interactive tools to see where they are—and the congressional districts they’re in.
Walking into your favorite restaurant and seeing a robot chef in the kitchen may seem far-fetched, but new research suggests that bots could be a solution to persistent labor shortages in the industry.
Johns Hopkins University engineers have developed a pioneering prosthetic hand that can grip plush toys, water bottles, and other everyday objects like a human, carefully conforming and adjusting its grasp to avoid damaging or mishandling whatever it holds.
Contextual AI launches its Grounded Language Model (GLM) that achieves 88% factual accuracy, outperforming major competitors while minimizing hallucinations for enterprise applications.Read More
The imposition of tariffs on Mexico and Canada represents a violation of the USMCA and could trigger a tariff war, experts say.
Researchers have demonstrated that multicolored stickers applied to stop or speed limit signs on the roadside can ‘confuse’ self-driving vehicles, causing unpredictable and possibly hazardous operations.
A small team of AI engineers at Zoom Communications has developed a new approach to training AI systems that uses far fewer resources than the standard approach now in use. The team has published their results on the arXiv preprint server.
Zoom researchers unveil “chain of draft,” which cuts AI token usage by 92%, transforming the economics of language model deployment.Read More
New SEC filings from pharmaceutical companies reveal Donald Trump and Elon Musk’s cost-cutting measures could slow drug research and delay FDA approvals.